Value through Innovation27 July 2016

What is a lay summary?

To view this video in other translations click on the language below:
Chinese (simplified)
Chinese (traditional)
Portuguese (Brazilian)

Clinical Study Results

  • Tiotropium - Pulmonary Disease, Chronic Obstructive
    Clinical Study Number 1249.1
    Study Indication Pulmonary Disease, Chronic Obstructive
    Product Tiotropium
    Generic Name Tiotropium + Salmeterol + Fluticasone; Tiotropium+ Salmeterol + Ciclesonide
    Lab Code
    Clinical Phase II
    Study Title

    A Randomised, Phase II, Double-Blind, Double-Dummy, four-period Crossover Efficacy and Safety Comparison of 4-Week Treatment Periods of Blinded Fluticasone (500 mcg bid, MDI), Ciclesonide (400 mcg qd, MDI), Ciclesonide (800 mcg qd, MDI) or placebo in Free Combination with Open-Label Tiotropium (18 mcg qd, HandiHaler) and Salmeterol (50 mcg bid, Diskus) in Patients with COPD

    Study Document
    Trial synopsis 1249.1_DR english